Amgen 2Q11 2Q Revenues: $4.0 billion (+4%) 2Q Earnings: $1.2 billion (-3%) YTD Revenues: $7.7 billion (+4%) YTD Earnings: $2.3 billion (-3%) Comments: Product revenues grew 8% in 2Q11 to $3.9 billion. U.S. sales rose 7% to $2.8 billion while international sales were up 11% to $918 million, with 4% accounted for by exchange rates. Epogen and Aranesp sales both fell in 2Q, offset by growth in Neulasta sales (+18% to $1.0 billion) and Enbrel (+9% to $1.0 billion). The company’s two denos...